• Peyronie's Disease
• Plantar Fibromatosis
• Dupuytren's Disease
• Healthcare Professionals

Company News

August 10, 2007

Transdermal Verapamil 15% Gel Selected as a Top Ten Innovation in Podiatric Care by Podiatry Today.

August 10, 2007, San Antonio, TX- PDLabs' Transdermal Verapamil 15% Gel has been selected by Podiatry Today as one of the top 10 innovations in podiatry in their annual product review. The article highlighted the medications ability to reduce the pain that is associated with plantar fibromatosis and the study that is currently underway that demonstrates the medications ability to remodel and reduce the size of the associated fibromas.

Robert Schulte, DPM, the principal investigator of the study, was interviewed for the article and explained that "there are no other good options" for treating plantar fibromatosis and that the topical application of the medication is advantageous. Dr. Schulte "could not recall one patient that did not have pain reduction with the gel."

"We are pleased that our medication was selected by Podiatry Today," said Jerry Easterling, CEO of PDLabs. "Our goal is to provide non-invasive treatment options to Podiatrists for conditions such as plantar fibromatosis that can be challenging to treat. We look forward to continuing our commitment to podiatry."

PDLabs primary focus is to develop non-invasive treatments for fibrotic tissue disorders. The company is currently conducting pilot studies for other conditions that, if successful, will have applications in podiatry and dermatology.

Copyright © 2007 PDLabs Inc. All rights reserved. Privacy Policy.

The information contained in this website is provided for educational purposes only and is not intended to replace discussions with your healthcare provider. All decisions regarding a patients' treatment must be made with a healthcare provider.

Transdermal Verapamil 15% Gel is available as a compounded medication exclusively from PDLabs. Transdermal Verapamil 15% Gel is not FDA approved. PDLabs is not an "internet pharmacy" and requires that an appropriate doctor-patient-pharmacist relationship be maintained. PDLabs will not fill prescriptions for patients that do not have a valid patient-doctor relationship.

Transdermal Verapamil 15% Gel is not for everyone. Patients with specific heart conditions known as atrioventricular (AV) block or Sino-Atrial (SA) block should not use calcium channel blockers such as verapamil. Patients taking the antiarrhythmic drug Tikosyn® (Dofetilide) should not use Transdermal Verapamil 15% Gel.

Patients taking digoxin or cyclosporine should have their drug levels monitored on a regular basis as verapamil may decrease the metabolism and clearance of these drugs. Patients taking antiarrhythmic drugs should consult with their doctor before taking Transdermal Verapamil 15% Gel to ensure it is safe to use. A PDLabs pharmacist can help with this discussion.

The most common side effect reported with Transdermal Verapamil 15% Gel, affecting 3-5% of Peyronie's disease patients, is varying degrees of skin irritation. Some patients using the medication for the first time may experience mild itching/irritation during the first few days of treatment. This is normal and usually resolves within 3-4 days. Other patients may experience more severe contact dermatitis, including itching, burning, redness, or swelling. More persistent or severe irritation can usually be treated with topical corticosteroids. Based on the individual symptoms, PDLabs will work with the patient and prescribing physician to determine the best course of treatment to resolve irritation.